Allodynic Therapeutics, LLC   Report issue

For profit Phase 2 Phase 3
Founded: North Miami FL United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2011
NCT01415895
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Allodynic Therapeutics, Inc | Allodynic Therapeutics, LLC | Annette C. Toledano MD

Active Ingredients

Drugs in Phase 3 Trials (2)

naltrexone (revia) (6 trials)

sumatriptan (zecuity) (1 trial)

Drugs in Phase 2 Trials (1)

acetaminophen (tylenol) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 2)

Facial Pain (Phase 3)

Facies (Phase 3)

Low Back Pain (Phase 2)

Migraine Disorders (Phase 3)

Neck Pain (Phase 2)

Neuralgia (Phase 3)

Trigeminal Neuralgia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3